Publikationen 2024

Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Broeckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Duehrsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA:(2024)Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.Leukemia. 2024;38(1): 160-167
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge WA, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M:(2024)Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.Blood Adv. 2024;8(8): 1857-1868
Taubmann J, Müller F, Yalcin Mutlu M, Völkl S, Aigner M, Bozec A, Mackensen A, Grieshaber-Bouyer R, Schett G:(2024)CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.Arthritis Rheumatol. 2024;76(4): 497-504
Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, Martin S, Schwab K, Serve H, Reiser L, Knaden J, Pfeifer H, Marx J, Sauer T, Berdel WE, Lenz G, Brüggemann M, Gökbuget N, Wethmar K:(2024)Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.J Clin Oncol. 2024;42(3): 273-282
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro PA, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I, Farge D:(2024)Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee.EClinicalMedicine. 2024;69():
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, Kretschmann S, Boeltz S, Atzinger A, Kuwert T, Roemer F, Uder M, Mackensen A, Schett G:(2024)Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.Rheumatology (Oxford). 2024;63(1): e12-e14
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA:(2024)Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.Leukemia. 2024;38(1): 160-167
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G:(2024)CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.N Engl J Med. 2024;390(8): 687-700
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C:(2024)Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.J Clin Oncol. 2024;42(14): 1665-1675
Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan CD, Cheng JK, Van Blarcom T, Schett G, Mackensen A, Lutzny-Geier G:(2024)Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.Transplant Cell Ther. 2024;30(6): 582.e1-582.e10
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, Von Stackelberg A, Peters C:(2024)Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.Haematologica. 2024;109(12): 3892-3903
Metz-Zumaran C, Uckeley ZM, Doldan P, Muraca F, Keser Y, Lukas P, Kuropka B, Küchenhoff L, Rastgou Talemi S, Höfer T, Freund C, Cavalcanti-Adam EA, Graw F, Stanifer M, Boulant S:(2024)The population context is a driver of the heterogeneous response of epithelial cells to interferons.Mol Syst Biol. 2024;20(3): 242-275
Alamoudi E, Reck F, Bundgaard N, Graw F, Brusch L, Hasenauer J, Schälte Y:(2024)A wall-time minimizing parallelization strategy for approximate Bayesian computation.PLoS ONE. 2024;19(2):
Richter S, Böttcher M, Stoll A, Zeremski V, Völkl S, Mackensen A, Ekici AB, Jacobs B, Mougiakakos D:(2024)Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.Transplant Cell Ther. 2024;30(6): 628.e1-628.e9
Schewe DM, Vogiatzi F, Münnich IA, Zeller T, Windisch R, Wichmann C, Müller K, Bhat H, Felix E, Mougiakakos D, Bruns H, Lenk L, Valerius T, Humpe A, Peipp M, Kellner C:(2024)Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.Hemasphere. 2024;8(2):
Schreiber L, Ghimire S, Hiergeist A, Renner K, Althammer M, Babl N, Peuker A, Schoenhammer G, Hippe K, Gessner A, Albrecht C, Pielmeier F, Büttner-Herold M, Bruns H, Hoffmann P, Herr W, Holler E, Peter K, Kreutz M, Matos C:(2024)Strain specific differences in vitamin D3 response: impact on gut homeostasis.Front Immunol. 2024;15():
Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Dell'Orso G, Aigner M, Fecker G, Hinze C, Wittkowski H, Bruns H, Zierk J, Metzler M, Arkwright PD, Graw F, Mackensen A, Völkl S:(2024)Detection of signature double-negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function.Am J Hematol. 2024;99(5): 997-1000
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk FA, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf TH, Hofmann WK, Klein S, Jost E, Reiter A, Panse J:(2024)Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.Leukemia. 2024;38(4): 810-821
Winkler J, Tittlbach H, Schneider A, Vasova I, Strobel J, Herold S, Maas S, Spriewald BM, Repp R, Kordelas L, Mach M, Wolff D, Edinger M, Mackensen A, Winkler TH:(2024)Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.Blood Adv. 2024;8(10): 2373-2383
Schlieben LD, Carta MG, Moskalev EA, Stöhr R, Metzler M, Besendörfer M, Meidenbauer N, Semrau S, Janka R, Grützmann R, Wiemann S, Hartmann A, Agaimy A, Haller F, Ferrazzi F:(2024)Machine Learning-Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing.J Mol Diagn. 2024;26(5): 387-398
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C:(2024)Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.Clin Cancer Res. 2024;30(16): 3564-3577
Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Schubert J, Niederland J, Kaufmann M, Schäfer-Eckart K, Schaich M, Baldauf H, Stölzel F, Petzold C, Röllig C, Alakel N, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Bornhäuser M, Mikesch JH, Schetelig J, Study Alliance Leukemia and the German Cooperative Transplant Study Group , Alakel N, Albring J, Berdel WE, Bethge W, Bornhäuser M, Bug G, Buhl C, Call S, Crysandt M, Egger-Heidrich K, Eßeling E, Faul C, Franke GN, Georgi JA, Glück-Wolf J, Groth C, Hauptrock B, Heidenreich D, Janjetovic S, Jost E, Kaufmann M, Kindler T, Klein SA, Krause SW, Kreil S, Kretschmann T, Kunadt D, Lang F, Lenz G, Martin S, Marx J, Middeke JM, Mikesch JH, Müller LP, Müller N, Niederland J, Parmentier S, Petzold K, Platzbecker U, Rank A, Reicherts C, Röllig C, Rösler W, Schäfer-Eckart K, Schaffrath J, Schaich M, Schetelig J, Schliemann C, Schmid C, Schneidawind D, Schubert J, Serve H, Sockel K, Steffen B, Stelljes M, Teipel R, von Bonin M, Wagner-Drouet E, Wass M, Wendelin K:(2024)Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.Lancet Haematol. 2024;11(5): e324-e335
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM:(2024)A Day 14 Endpoint for Acute GVHD Clinical Trials.Transplant Cell Ther. 2024;30(4): 421-432
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk FA, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter-Finkelstein T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng GW, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R:(2024)Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.Blood Adv. 2024;8(8): 2047-2057
Zeremski V, Adolph L, Beer S, Berisha M, Jacobs B, Kahl C, Koenecke C, Kropf S, Panse J, Petersen J, Schmidt-Hieber M, Schneider J, Vucinic V, Walter J, Weigert O, Witte HM, Mougiakakos D:(2024)Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.Eur J Haematol. 2024;112(4): 641-649
Kocher K, Moosmann C, Drost F, Schülein C, Irrgang P, Steininger P, Zhong J, Träger J, Spriewald B, Bock C, Busch DH, Bogdan C, Schubert B, Winkler TH, Tenbusch M, Schuster EM, Schober K:(2024)Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.Lancet Infect Dis. 2024;24(5): e272-e274
Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, Schwartz S, Steffen B, Spriewald B, Heinicke T, Jäkel N, Westermann J, Nachtkamp K, Viardot A, Topp MS, Neumann M, Baldus CD, Gökbuget N, Brüggemann M:(2024)Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.Leukemia. 2024;38(7): 1600-1603
Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S, Vasova I, Völkl S, Woelfle J, Mackensen A, Schett G, Metzler M, Müller F:(2024)CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.Lancet. 2024;403(10437): 1627-1630
Liang C, Spoerl S, Xiao Y, Habenicht KM, Haeusl SS, Sandner I, Winkler J, Strieder N, Eder R, Stanewsky H, Alexiou C, Dudziak D, Rosenwald A, Edinger M, Rehli M, Hoffmann P, Winkler TH, Berberich-Siebelt F:(2024)Oligoclonal CD4+CXCR5+ T cells with a cytotoxic phenotype appear in tonsils and blood.Commun Biol. 2024;7(1):
Cuba L, Dürr P, Gessner K, Häcker B, Fietkau R, Siebler J, Pavel M, Neurath MF, Berking C, Wullich B, Brückl V, Beckmann MW, Fromm MF, Dörje F:(2024)A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.JCO Oncol Pract. 2024;20(9): 1219-1230
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L:(2024)Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.Haematologica. 2024;109(8): 2469-2477
Bruns H:(2024)Treg depletion supercharges ASCT power.Blood. 2024;143(16): 1562-1563
Wilhelm A, Chambers D, Müller F, Bozec A, Grieshaber-Bouyer R, Winkler T, Mougiakakos D, Mackensen A, Schett G, Krönke G:(2024)Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE.JCI Insight. 2024;9(12):
Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, Retzlaff J, Dörrie J, Schaft N, Wiesinger M, März J, Schuler-Thurner B, Knorr H, Gupta S, Singh KP, Schuler G, Heppt MV, Koch EAT, van Kleef ND, Freen-van Heeren JJ, Turksma AW, Wolkenhauer O, Hohberger B, Berking C, Bruns H, Vera J:(2024)Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.J Immunother Cancer. 2024;12(5):
de Jong MME, Fokkema C, Papazian N, Czeti Á, Appelman MK, Vermeulen M, van Heusden T, Hoogenboezem RM, van Beek G, Tahri S, Sanders MA, van de Woestijne PC, Gay F, Moreau P, Büttner-Herold M, Bruns H, van Duin M, Broijl A, Sonneveld P, Cupedo T:(2024)An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.Nat Immunol. 2024;25(5): 820-833
Behzad A, Feldmann-Schulz C, Lenz B, Clarkson L, Ludwig C, Luttenberger K, Völkl S, Kornhuber J, Mühle C, von Zimmermann C:(2024)TaKeTiNa Music Therapy for Outpatient Treatment of Depression: Study Protocol for a Randomized Clinical Trial.J Clin Med. 2024;13(9):
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R:(2024)Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.Nat. Cancer. 2024;5(8): 1227-1249
Hagen M, Wirsching A, Bohr D, Taubmann J, Mueller F, Mackensen A, Grieshaber-Bouyer R, Schett G:(2024)[CAR T-cell therapy in rheumatology-What we know so far?].Z Rheumatol. 2024;83(6): 485-491
Agaimy A, Dermawan JK, Haller F, Semrau S, Meidenbauer N, Stoehr R, Lax S, Hartmann A, Zou YS, Xing D, Tögel L, Gross JM, Michal M:(2024)ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.Virchows Arch. 2024;485(5): 805-813
Agaimy A, Blakely M, Breimer GE, Hölsken A, Koppes SA, Meidenbauer N, Rijken JA, Schad A, Simon AG, Stoehr R, Bishop JA, Din NU:(2024)Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites.Virchows Arch. 2024;485(6): 1007-1019
Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, Haghikia A, Merkel PA, Caricchio R, D'Agostino MA, Locatelli F, June CH, Mougiakakos D:(2024)Advancements and challenges in CAR T cell therapy in autoimmune diseases.Nat Rev Rheumatol. 2024;20(9): 531-544
Krebs M, Haller F, Spörl S, Gerhard-Hartmann E, Utpatel K, Maurus K, Kunzmann V, Chatterjee M, Venkataramani V, Maatouk I, Bittrich M, Einwag T, Meidenbauer N, Tögel L, Hirsch D, Dietmaier W, Keil F, Scheiter A, Immel A, Heudobler D, Einhell S, Kaiser U, Sedlmeier AM, Maurer J, Schenkirsch G, Jordan F, Schmutz M, Dintner S, Rosenwald A, Hartmann A, Evert M, Märkl B, Bargou R, Mackensen A, Beckmann MW, Pukrop T, Herr W, Einsele H, Trepel M, Goebeler ME, Claus R, Kerscher A, Lüke F:(2024)The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany.Eur J Cancer. 2024;207():
Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, Altmeyer S, Bittenbring JT, Augsberger C, Ilieva-Babinsky K, Haskamp S, Beier F, Lischer C, Vera J, Lührmann A, Bertz S, Völkl S, Jacobs B, Steidl S, Mackensen A, Bruns H:(2024)Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.Haematologica. 2024;109(12): 3928-3940
Abir AH, Weckwerth L, Wilhelm A, Thomas J, Reichardt CM, Munoz L, Völkl S, Appelt U, Mroz M, Niesner R, Hauser A, Sophie Fischer R, Pracht K, Jäck HM, Schett G, Krönke G, Mielenz D:(2024)Metabolic profiling of single cells by exploiting NADH and FAD fluorescence via flow cytometry.Mol Metab. 2024;87():
Burkhard-Meier A, Grube M, Jurinovic V, Agaimy A, Albertsmeier M, Berclaz LM, Di Gioia D, Dürr HR, von Eisenhart-Rothe R, Eze C, Fechner K, Fey E, Güler SE, Hecker JS, Hendricks A, Keil F, Klein A, Knebel C, Kovács JR, Kunz WG, Lenze U, Lörsch AM, Lutz M, Meidenbauer N, Mogler C, Schmidt-Hegemann NS, Semrau S, Sienel W, Trepel M, Waldschmidt J, Wiegering A, Lindner LH:(2024)Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma - A retrospective multicenter study of the Bavarian university hospitals.Eur J Surg Oncol. 2024;50(12):
Küpper C, Erb TM, Träger J, Meintker L, Valenza G, Bogdan C, Held J:(2024)The Aspergillus galactomannan Ag VIRCLIA® Monotest and the sõna Aspergillus galactomannan lateral flow assay show comparable performance for the diagnosis of invasive aspergillosis.Mycoses. 2024;67(8):
Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, Jentzsch M, Sasca D, Moyses M, Fuhrmann S, Gundel D, Caduc M, Teichmann LL, Heidel F, Al-Ali HK, Petrides PE:(2024)MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.Ann Hematol. 2024;103(10): 4065-4077
Wrage M, Holland T, Nüse B, Kaltwasser J, Fröhlich J, Arnold H, Gießler C, Flamann C, Bruns H, Berges J, Daniel C, Hoffmann MH, Anish C, Seeberger PH, Bogdan C, Dettmer K, Rauh M, Mattner J:(2024)Cell type-specific modulation of metabolic, immune-regulatory, and anti-microbial pathways by CD101.Mucosal Immunol. 2024;17(5): 892-910
Ziemann M, Lindemann M, Hallensleben M, Altermann W, Althaus K, Budde K, Einecke G, Eisenberger U, Ender A, Feldkamp T, Grahammer F, Guthoff M, Holzmann-Littig C, Hugo C, Kauke T, Kemmner S, Koch M, Lachmann N, Marget M, Morath C, Nitschke M, Renders L, Scherer S, Stumpf J, Schwenger V, Sommer F, Spriewald B, Süsal C, Zecher D, Heinemann FM, Verboom M:(2024)Risk Stratification Before Living Donor Kidney Transplantation in Patients With Preformed Donor-specific Antibodies by Different Crossmatch Methods.Transplant Direct. 2024;10(9):
Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N, French Lymphoma Study Association (LYSA), the Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), and the German Lymphoma Alliance (GLA):(2024)Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).J Clin Oncol. 2024;42(32): 3788-3794
Etra A, El Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk F, Baez J, Betts BC, Chanswangphuwana C, Chen YB, Choe H, DeFilipp Z, Gleich S, Hexner E, Hogan WJ, Holler E, Kitko CL, Kraus S, Al Malki M, MacMillan M, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter T, Vasova I, Weisdorf D, Wölfl M, Young R, Nakamura R, Ferrara JLM, Levine JE, Holtan S:(2024)Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.Blood Adv. 2024;8(12): 3284-3292
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Nakamura R, Levine JE, Ferrara JLM:(2024)Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.Blood. 2024;144(9): 1010-1021
Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y:(2024)Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.Transplant Cell Ther. 2024;30(11): 1061.e1-1061.e10
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara JLM, Nakamura R, Levine JE, Chen YB:(2024)The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.Blood Adv. 2024;8(13): 3488-3496
Theil F, Kuckhahn A, Hörning A, Völkl S, Knab K, Fritz N, Gräbner C, Ramsperger-Gleixner M, Weyand M, Heim C:(2024)Repeated CXCR4 Blockade by Plerixafor Attenuates Transplant Vasculopathy in Murine Aortic Allografts.J Immunol. 2024;213(10): 1542-1552
Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Aigner M, Völkl S, Köhler B, Dörfler A, Grieshaber-Bouyer R, Mackensen A, Schett G:(2024)Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.Lancet. 2024;404(10468): 2158-2160
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N:(2024)Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.Blood Cancer J. 2024;14(1):
Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfò L, Morelli F, Galli E, Martini F, Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI, Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V, Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A, Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R, Laurenti L:(2024)Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.Hemasphere. 2024;8(12):
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M:(2024)Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.Leukemia. 2024;38(5): 1072-1080
Müller F:(2024)Fabian Müller.Med (N Y). 2024;5(6): 479-481

Publikationen 2024

Publikationen 2024

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre